Stanford

Rondeep Brar

Clinical Professor, Medicine - Hematology

CLINICAL OFFICE (PRIMARY)

- **Stanford Comprehensive Cancer Center**
  875 Blake Wilbur Dr Rm 2327
  MC 6560
  Stanford, CA 94305
  Tel (650) 498-6000 **Fax** (650) 724-5203

ACADEMIC CONTACT INFORMATION

- **Stanford Cancer Center**
  Tel (650) 498-6000

Bio

BIO

As the Chief Medical Officer of Cancer Care at Stanford Health Care, it is my privilege to partner with my colleagues in advancing innovative research alongside high quality, coordinated, and compassionate care.

I aim to provide high quality care in a diverse patient practice. My clinic includes all types of hematologic disorders, ranging from anemia, clotting/ bleeding disorders, and low blood counts to complex malignancies such as leukemia, myelodysplastic syndrome, myeloma, and lymphoma. I aim to combine the efficiency of a private office with the complex care expected of a tertiary institution like Stanford. I value your time and strive to maintain an on-schedule clinic.

CLINICAL FOCUS

- Cancer > Hematology
- Hematology
- Oncology

ACADEMIC APPOINTMENTS

- Clinical Professor, Medicine - Hematology

ADMINISTRATIVE APPOINTMENTS

- Chief Medical Officer, Cancer Care, Stanford Health Care, (2025- present)
- Ann and John Doerr Medical Director of the Stanford Cancer Center, Stanford Cancer Center, (2023- present)

HONORS AND AWARDS

- Denise O'Leary Award for Clinical Excellence, Stanford Health Care (2025)

PROFESSIONAL EDUCATION

- Medical Education: UCLA David Geffen School Of Medicine (2007) CA

- Board Certification: Medical Oncology, American Board of Internal Medicine (2013)
- Board Certification: Hematology, American Board of Internal Medicine (2013)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2012) CA
- Residency: Stanford University Internal Medicine Residency (2010) CA

Research & Scholarship

CLINICAL TRIALS

- (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive, Not Recruiting
- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy, Not Recruiting
- A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia, Not Recruiting
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy, Not Recruiting
- A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome, Not Recruiting
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL, Not Recruiting
- An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study, Not Recruiting
- Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML), Not Recruiting
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia, Not Recruiting
- CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome, Not Recruiting
- Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion, Not Recruiting
- Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas, Not Recruiting
- Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission, Not Recruiting
- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma, Not Recruiting
- Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis, Not Recruiting
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia, Not Recruiting
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia, Not Recruiting
- S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia, Not Recruiting
- S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia, Not Recruiting
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML), Not Recruiting
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML), Not Recruiting
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL), Not Recruiting
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma, Not Recruiting
- Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Not Recruiting

- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia, Not Recruiting

Publications

PUBLICATIONS

- **Real time machine learning prediction of next generation sequencing test results in live clinical settings.** *NPJ digital medicine*
  Kim, G. Y., Schwede, M., Corbin, C. K., Fouladvand, S., Brar, R., Iberri, D., Shomali, W., Oak, J. S., Gratzinger, D., Stehr, H., Chen, J. H.
  2025; 8 (1): 533

- **Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3, and MPL mutations.** *Blood advances*
  Zhang, H., Chien, M., Hou, Y., Shomali, W., Brar, R., Ho, C., Han, P., Xu, D., Zhang, B. M., Guo, X., Tolentino, L., Wu, N. C., Tsai, et al
  2022

- **Machine Learning Predictability of Clinical Next Generation Sequencing for Hematologic Malignancies to Guide High-Value Precision Medicine.** *AMIA ... Annual Symposium proceedings. AMIA Symposium*
  Kim, G. Y., Noshad, M., Stehr, H., Rojansky, R., Gratzinger, D., Oak, J., Brar, R., Iberri, D., Kong, C., Zehnder, J., Chen, J. H.
  2021; 2021: 641-650

- **A Case of G6PC3 Congenital Neutropenia, Misdiagnosed As Evans Syndrome**
  Camacho, J., Brar, R., Chapman, C., Fernandez-Pol, S., Weinacht, K., Gernez, Y.
  SPRINGER/PLENUM PUBLISHERS.2020: S131–S132

- **Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes.** *Surgery open science*
  Alobuia, W. M., Perrone, K. n., Iberri, D. J., Brar, R. S., Spain, D. A., Forrester, J. D.
  2020; 2 (4): 19–24

- **Late presentation of dyskeratosis congenita.** *British journal of haematology*
  Shomali, W., Brar, R.
  2019

- **A Kindred with a β-Globin Base Substitution [β89(F5)Ser→Arg (AGT>AGG); HBB: c.270T>G] Resulting in Hemoglobin Vanderbilt.** *Hemoglobin*
  Shomali, W. n., Brar, R. n., Arekapudi, S. R., Gotlib, J. R.
  2019: 1–4